LambdaGen Therapeutics

Executive Summary

LambdaGen Therapeutics is a Singapore-based preclinical biotech that has developed LIGIT, a proprietary λ-integrase genome engineering platform capable of inserting large DNA payloads (>10 kb) into safe-harbor sites with high precision and stability. The company is leveraging this platform to create off-the-shelf CAR-NK cell therapies targeting B-cell lymphoma, aiming to overcome the limitations of viral vectors and autologous CAR-T therapies. Additionally, LambdaGen is engineering cell lines for stable, high-yield production of anti-PD-1 antibodies, and offers seamless vector construction and cell-line engineering services to partners. Founded in 2020 and employing 50–200 staff, the company is positioned to address key bottlenecks in cell and gene therapy manufacturing and therapeutic development. While still in preclinical stages, LambdaGen’s platform-agnostic approach and service revenue model provide a diversified risk profile. The company’s ability to deliver large genetic payloads at specific genomic loci differentiates it from CRISPR-based or viral-vector methods. Near-term value inflection points include the release of in vivo efficacy data for its lead CAR-NK candidate, potential platform validation through licensing or collaboration deals, and a Series A fundraising round to advance programs toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Preclinical efficacy data readout for lead CAR-NK program in B-cell lymphoma40% success
• H1 2027Platform licensing or co-development partnership with a larger biopharma30% success
• Q3 2026Series A financing to support IND-enabling studies50% success